Patient-Reported Quality of Life Outcomes after Moderately Hypofractionated and Normofractionated Proton Therapy for Localized Prostate Cancer
We retrospectively evaluated the three-year patient-reported quality of life (QOL) after moderately hypofractionated proton therapy (MHPT) for localized prostate cancer in comparison with that after normofractionated PT (NFPT) using the Expanded Prostate Cancer Index Composite-50. Patients who recei...
Gespeichert in:
| Veröffentlicht in: | Cancers 2022-01, Vol.14 (3), p.517 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 3 |
| container_start_page | 517 |
| container_title | Cancers |
| container_volume | 14 |
| creator | Nakajima, Koichiro Iwata, Hiromitsu Hattori, Yukiko Nomura, Kento Hayashi, Kensuke Toshito, Toshiyuki Umemoto, Yukihiro Hashimoto, Shingo Ogino, Hiroyuki Shibamoto, Yuta |
| description | We retrospectively evaluated the three-year patient-reported quality of life (QOL) after moderately hypofractionated proton therapy (MHPT) for localized prostate cancer in comparison with that after normofractionated PT (NFPT) using the Expanded Prostate Cancer Index Composite-50. Patients who received MHPT (60-63 Gy (relative biological effectiveness equivalents; RBE)/20-21 fractions) (
= 343) or NFPT (74-78 Gy (RBE)/37-39 fractions) (
= 296) between 2013 and 2016 were analyzed. The minimum clinically important difference (MCID) threshold was defined as one-half of a standard deviation of the baseline value. The median follow-up was 56 months and 83% completed questionnaires at 36 months. Clinically meaningful score deterioration was observed in the urinary domain at 1 month in both groups and in the sexual domain at 6-36 months in the NFPT group, but not observed in the bowel domain. At 36 months, the mean score change for urinary summary was -0.3 (MHPT) and -1.6 points (NFPT), and that for bowel summary was +0.1 and -2.0 points; the proportion of patients with MCID was 21% and 24% for urinary summary and 18% and 29% for bowel summary. Overall, MHPT had small negative impacts on QOL over three years, and the QOL after MHPT and NFPT was similar. |
| doi_str_mv | 10.3390/cancers14030517 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8833499</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2627528249</sourcerecordid><originalsourceid>FETCH-LOGICAL-c487t-90cb72302e19bc36f4e4d4791abb7c32c6ed7fefbd8bf42fc352cbedadbacb1a3</originalsourceid><addsrcrecordid>eNpdkUtv1TAQhS0EolXpmh2yxIZNqF-J4w0SuioU6UILKuvIjzFNlcTBdpDCj-hvri-3VG29seX55thnDkKvKXnPuSInVk8WYqKCcFJT-QwdMiJZ1TRKPH9wPkDHKV2TsjinspEv0QGvad3Ktj5ENxc69zDl6gfMIWZw-Puihz6vOHi87T3g8yXbMELC2meI-GtwEHWGYcVn6xx81Db3YdK7Vj05_C3E8fHtRQw5TPjyqvTNK_Yh4m2w5ZG_-2LKBcObf2ZeoRdeDwmO7_Yj9PPT6eXmrNqef_6y-bitrGhlrhSxRjJOGFBlLG-8AOGEVFQbIy1ntgEnPXjjWuMF85bXzBpw2hltDdX8CH3Y686LGcHZMoGoh26O_ajj2gXdd48rU3_V_Qp_urblXChVBN7dCcTwe4GUu7FPFoZBTxCW1LGGKVK3itcFffsEvQ5LnIq9HSVr1jKxEzzZU7ZMJEXw95-hpNvF3T2Ju3S8eejhnv8fLr8FrAys8g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2627528249</pqid></control><display><type>article</type><title>Patient-Reported Quality of Life Outcomes after Moderately Hypofractionated and Normofractionated Proton Therapy for Localized Prostate Cancer</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>Nakajima, Koichiro ; Iwata, Hiromitsu ; Hattori, Yukiko ; Nomura, Kento ; Hayashi, Kensuke ; Toshito, Toshiyuki ; Umemoto, Yukihiro ; Hashimoto, Shingo ; Ogino, Hiroyuki ; Shibamoto, Yuta</creator><creatorcontrib>Nakajima, Koichiro ; Iwata, Hiromitsu ; Hattori, Yukiko ; Nomura, Kento ; Hayashi, Kensuke ; Toshito, Toshiyuki ; Umemoto, Yukihiro ; Hashimoto, Shingo ; Ogino, Hiroyuki ; Shibamoto, Yuta</creatorcontrib><description>We retrospectively evaluated the three-year patient-reported quality of life (QOL) after moderately hypofractionated proton therapy (MHPT) for localized prostate cancer in comparison with that after normofractionated PT (NFPT) using the Expanded Prostate Cancer Index Composite-50. Patients who received MHPT (60-63 Gy (relative biological effectiveness equivalents; RBE)/20-21 fractions) (
= 343) or NFPT (74-78 Gy (RBE)/37-39 fractions) (
= 296) between 2013 and 2016 were analyzed. The minimum clinically important difference (MCID) threshold was defined as one-half of a standard deviation of the baseline value. The median follow-up was 56 months and 83% completed questionnaires at 36 months. Clinically meaningful score deterioration was observed in the urinary domain at 1 month in both groups and in the sexual domain at 6-36 months in the NFPT group, but not observed in the bowel domain. At 36 months, the mean score change for urinary summary was -0.3 (MHPT) and -1.6 points (NFPT), and that for bowel summary was +0.1 and -2.0 points; the proportion of patients with MCID was 21% and 24% for urinary summary and 18% and 29% for bowel summary. Overall, MHPT had small negative impacts on QOL over three years, and the QOL after MHPT and NFPT was similar.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers14030517</identifier><identifier>PMID: 35158785</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Androgens ; Cancer therapies ; Intestine ; Patients ; Prostate cancer ; Quality of life ; Radiation therapy ; Rectum</subject><ispartof>Cancers, 2022-01, Vol.14 (3), p.517</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c487t-90cb72302e19bc36f4e4d4791abb7c32c6ed7fefbd8bf42fc352cbedadbacb1a3</citedby><cites>FETCH-LOGICAL-c487t-90cb72302e19bc36f4e4d4791abb7c32c6ed7fefbd8bf42fc352cbedadbacb1a3</cites><orcidid>0000-0003-1307-7608 ; 0000-0002-6762-0015 ; 0000-0002-7525-0288 ; 0000-0001-9809-9800</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833499/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833499/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,886,27926,27927,53793,53795</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35158785$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nakajima, Koichiro</creatorcontrib><creatorcontrib>Iwata, Hiromitsu</creatorcontrib><creatorcontrib>Hattori, Yukiko</creatorcontrib><creatorcontrib>Nomura, Kento</creatorcontrib><creatorcontrib>Hayashi, Kensuke</creatorcontrib><creatorcontrib>Toshito, Toshiyuki</creatorcontrib><creatorcontrib>Umemoto, Yukihiro</creatorcontrib><creatorcontrib>Hashimoto, Shingo</creatorcontrib><creatorcontrib>Ogino, Hiroyuki</creatorcontrib><creatorcontrib>Shibamoto, Yuta</creatorcontrib><title>Patient-Reported Quality of Life Outcomes after Moderately Hypofractionated and Normofractionated Proton Therapy for Localized Prostate Cancer</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>We retrospectively evaluated the three-year patient-reported quality of life (QOL) after moderately hypofractionated proton therapy (MHPT) for localized prostate cancer in comparison with that after normofractionated PT (NFPT) using the Expanded Prostate Cancer Index Composite-50. Patients who received MHPT (60-63 Gy (relative biological effectiveness equivalents; RBE)/20-21 fractions) (
= 343) or NFPT (74-78 Gy (RBE)/37-39 fractions) (
= 296) between 2013 and 2016 were analyzed. The minimum clinically important difference (MCID) threshold was defined as one-half of a standard deviation of the baseline value. The median follow-up was 56 months and 83% completed questionnaires at 36 months. Clinically meaningful score deterioration was observed in the urinary domain at 1 month in both groups and in the sexual domain at 6-36 months in the NFPT group, but not observed in the bowel domain. At 36 months, the mean score change for urinary summary was -0.3 (MHPT) and -1.6 points (NFPT), and that for bowel summary was +0.1 and -2.0 points; the proportion of patients with MCID was 21% and 24% for urinary summary and 18% and 29% for bowel summary. Overall, MHPT had small negative impacts on QOL over three years, and the QOL after MHPT and NFPT was similar.</description><subject>Androgens</subject><subject>Cancer therapies</subject><subject>Intestine</subject><subject>Patients</subject><subject>Prostate cancer</subject><subject>Quality of life</subject><subject>Radiation therapy</subject><subject>Rectum</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkUtv1TAQhS0EolXpmh2yxIZNqF-J4w0SuioU6UILKuvIjzFNlcTBdpDCj-hvri-3VG29seX55thnDkKvKXnPuSInVk8WYqKCcFJT-QwdMiJZ1TRKPH9wPkDHKV2TsjinspEv0QGvad3Ktj5ENxc69zDl6gfMIWZw-Puihz6vOHi87T3g8yXbMELC2meI-GtwEHWGYcVn6xx81Db3YdK7Vj05_C3E8fHtRQw5TPjyqvTNK_Yh4m2w5ZG_-2LKBcObf2ZeoRdeDwmO7_Yj9PPT6eXmrNqef_6y-bitrGhlrhSxRjJOGFBlLG-8AOGEVFQbIy1ntgEnPXjjWuMF85bXzBpw2hltDdX8CH3Y686LGcHZMoGoh26O_ajj2gXdd48rU3_V_Qp_urblXChVBN7dCcTwe4GUu7FPFoZBTxCW1LGGKVK3itcFffsEvQ5LnIq9HSVr1jKxEzzZU7ZMJEXw95-hpNvF3T2Ju3S8eejhnv8fLr8FrAys8g</recordid><startdate>20220120</startdate><enddate>20220120</enddate><creator>Nakajima, Koichiro</creator><creator>Iwata, Hiromitsu</creator><creator>Hattori, Yukiko</creator><creator>Nomura, Kento</creator><creator>Hayashi, Kensuke</creator><creator>Toshito, Toshiyuki</creator><creator>Umemoto, Yukihiro</creator><creator>Hashimoto, Shingo</creator><creator>Ogino, Hiroyuki</creator><creator>Shibamoto, Yuta</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1307-7608</orcidid><orcidid>https://orcid.org/0000-0002-6762-0015</orcidid><orcidid>https://orcid.org/0000-0002-7525-0288</orcidid><orcidid>https://orcid.org/0000-0001-9809-9800</orcidid></search><sort><creationdate>20220120</creationdate><title>Patient-Reported Quality of Life Outcomes after Moderately Hypofractionated and Normofractionated Proton Therapy for Localized Prostate Cancer</title><author>Nakajima, Koichiro ; Iwata, Hiromitsu ; Hattori, Yukiko ; Nomura, Kento ; Hayashi, Kensuke ; Toshito, Toshiyuki ; Umemoto, Yukihiro ; Hashimoto, Shingo ; Ogino, Hiroyuki ; Shibamoto, Yuta</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c487t-90cb72302e19bc36f4e4d4791abb7c32c6ed7fefbd8bf42fc352cbedadbacb1a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Androgens</topic><topic>Cancer therapies</topic><topic>Intestine</topic><topic>Patients</topic><topic>Prostate cancer</topic><topic>Quality of life</topic><topic>Radiation therapy</topic><topic>Rectum</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nakajima, Koichiro</creatorcontrib><creatorcontrib>Iwata, Hiromitsu</creatorcontrib><creatorcontrib>Hattori, Yukiko</creatorcontrib><creatorcontrib>Nomura, Kento</creatorcontrib><creatorcontrib>Hayashi, Kensuke</creatorcontrib><creatorcontrib>Toshito, Toshiyuki</creatorcontrib><creatorcontrib>Umemoto, Yukihiro</creatorcontrib><creatorcontrib>Hashimoto, Shingo</creatorcontrib><creatorcontrib>Ogino, Hiroyuki</creatorcontrib><creatorcontrib>Shibamoto, Yuta</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nakajima, Koichiro</au><au>Iwata, Hiromitsu</au><au>Hattori, Yukiko</au><au>Nomura, Kento</au><au>Hayashi, Kensuke</au><au>Toshito, Toshiyuki</au><au>Umemoto, Yukihiro</au><au>Hashimoto, Shingo</au><au>Ogino, Hiroyuki</au><au>Shibamoto, Yuta</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Patient-Reported Quality of Life Outcomes after Moderately Hypofractionated and Normofractionated Proton Therapy for Localized Prostate Cancer</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2022-01-20</date><risdate>2022</risdate><volume>14</volume><issue>3</issue><spage>517</spage><pages>517-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>We retrospectively evaluated the three-year patient-reported quality of life (QOL) after moderately hypofractionated proton therapy (MHPT) for localized prostate cancer in comparison with that after normofractionated PT (NFPT) using the Expanded Prostate Cancer Index Composite-50. Patients who received MHPT (60-63 Gy (relative biological effectiveness equivalents; RBE)/20-21 fractions) (
= 343) or NFPT (74-78 Gy (RBE)/37-39 fractions) (
= 296) between 2013 and 2016 were analyzed. The minimum clinically important difference (MCID) threshold was defined as one-half of a standard deviation of the baseline value. The median follow-up was 56 months and 83% completed questionnaires at 36 months. Clinically meaningful score deterioration was observed in the urinary domain at 1 month in both groups and in the sexual domain at 6-36 months in the NFPT group, but not observed in the bowel domain. At 36 months, the mean score change for urinary summary was -0.3 (MHPT) and -1.6 points (NFPT), and that for bowel summary was +0.1 and -2.0 points; the proportion of patients with MCID was 21% and 24% for urinary summary and 18% and 29% for bowel summary. Overall, MHPT had small negative impacts on QOL over three years, and the QOL after MHPT and NFPT was similar.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>35158785</pmid><doi>10.3390/cancers14030517</doi><orcidid>https://orcid.org/0000-0003-1307-7608</orcidid><orcidid>https://orcid.org/0000-0002-6762-0015</orcidid><orcidid>https://orcid.org/0000-0002-7525-0288</orcidid><orcidid>https://orcid.org/0000-0001-9809-9800</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2022-01, Vol.14 (3), p.517 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8833499 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central |
| subjects | Androgens Cancer therapies Intestine Patients Prostate cancer Quality of life Radiation therapy Rectum |
| title | Patient-Reported Quality of Life Outcomes after Moderately Hypofractionated and Normofractionated Proton Therapy for Localized Prostate Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T06%3A24%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Patient-Reported%20Quality%20of%20Life%20Outcomes%20after%20Moderately%20Hypofractionated%20and%20Normofractionated%20Proton%20Therapy%20for%20Localized%20Prostate%20Cancer&rft.jtitle=Cancers&rft.au=Nakajima,%20Koichiro&rft.date=2022-01-20&rft.volume=14&rft.issue=3&rft.spage=517&rft.pages=517-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers14030517&rft_dat=%3Cproquest_pubme%3E2627528249%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2627528249&rft_id=info:pmid/35158785&rfr_iscdi=true |